

TARGET

Intelligence Report

VOLUME XXIII No. 60

T H U R S D A Y

March 18, 2021

MEDIWELCOME HEALTHCARE MANAGEMENT AND TECHNOLOGY INCORPORATED: FULL MARKS FOR REFRESHING CANDOUR !

When Senior Management signs on the bottom line, indicating definitively that that which has been stated is a true and fair view in respect of all material matters, relating to the information, contained in a Global Offering Prospectus, it is far better to have been totally honest and forthright because, if it should be discovered that that which had been stated is far from being kosher, then, one may expect all kinds of problems to surface, down the rocky road to oblivion.

In the case of Mediwelcome Healthcare Management and Technology Incorporated (麥迪衛康健康醫療管理科技股份有限公司) (Code: 2159, Main Board, The Stock Exchange of Hongkong Ltd), however, one cannot not help but congratulate Senior Management on its seemingly refreshing candour.

Because, in the 641-Page Global Offering Prospectus, dated Thursday, December 31, 2020, it was clearly stated that, in the second half of the 2020 Financial Year, the Company suffered a Net Loss Attributable to Shareholders; and that, for the entire 2020 Financial Year, ended December 31, Senior Management had forecast a Net Profit Attributable to Shareholders of ‘*not less than 21 million renminbi (equivalent to \$HK24.80 million)*’.

If Senior Management is spot on, in its forecast profit in respect of the 2020 Financial Year – and **TARGET** (泰達財經) is quite certain that all is hunky-dory in respect of the Company’s profit prognosis – it would represent an increase, Year-On-Year, of about 148,000 renminbi (about \$HK176,610.00).

Which is, of course, far better than the Net Loss Attributable to Shareholders of 2,278,000 million renminbi (about \$HK2,718,360.00), recorded in respect of the six months, ended June 30, 2020.

The Initial Public Offering (IPO) Of Mediwelcome Healthcare Management And Technology Incorporated

Mediwelcome Healthcare Management and Technology Incorporated published and disseminated its Global Offering Prospectus in the **Hongkong Special Administrative Region (HKSAR)** of the **People’s Republic of China (PRC)** on Thursday, December 31, 2020.

Senior Management, of this provider of integrated healthcare marketing solutions market, sought to offload a total of 50 million, \$HK0.00001 Offer Shares at the Indicative Offer Price Per Share, within the range of \$HK3.00, the lowest acceptable Share Price, up to \$HK4.00, the highest level of the Indicative Offer Price range.

Investors of the HKSAR were Offered the opportunity to subscribe to five million Offer Shares (the HKSAR Offer Shares tranche) while (presumably) International Investors – Institutional Investors, Professional Investors, and select, Well-Heeled Investors, along with their corporate entities in which this class of investors was deemed to hold equity control, legally and beneficially – were induced to put in their valid applications for the remaining 45 million Offer Shares on offer (the International Offer Shares tranche).

On Monday, January 18, 2021, Management caused to have published an Announcement as to the Offer Price and Allotment Results.

In that Announcement, it was stated that the Offer Price Per Share had been struck at \$HK3.00 – the lowest level of the Indicative Offer Price range – and that Management envisaged that the Company's coffers would be enriched by the sum of about \$HK89.30 million.

With regard to ... [CLICK TO ORDER FULL ARTICLE](#)

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which they have read in TARGET, please feel free to e-mail your views to editor@targetnewspapers.com. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.